We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
-6.42%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$976M
AUM Growth
+$257M
(+36%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
28.55%
Top 10 Holdings %
Top 10 Hldgs %
76.43%
Holding
234
New
114
Increased
26
Reduced
16
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$370M |
| 2 |
American International
AIG
|
+$8.49M |
| 3 |
Ameriprise Financial
AMP
|
+$7.55M |
| 4 |
T. Rowe Price
TROW
|
+$7.55M |
| 5 |
Visa
V
|
+$6.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$85.7M |
| 2 |
FNB Corp
FNB
|
+$8.22M |
| 3 |
Travelers Companies
TRV
|
+$7.78M |
| 4 |
Sherwin-Williams
SHW
|
+$7.34M |
| 5 |
Willis Towers Watson
WTW
|
+$7.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.59% |
| 2 | Financials | 12.34% |
| 3 | Technology | 4.43% |
| 4 | Industrials | 4.41% |
| 5 | Consumer Discretionary | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Worthington Enterprises
WOR
$2.77B
| $1.36M | 0.14% |
+50,073
| New | +$1.34M |
|
|
IMMU
77
DELISTED
Immunomedics Inc
IMMU
| $1.36M | 0.14% |
+84,161
| New | +$993K |
|
78
Kennametal
KMT
$2.59B
| $1.36M | 0.14% |
+28,070
| New | +$1.25M |
|
79
Agios Pharmaceuticals
AGIO
$1.79B
| $1.36M | 0.14% |
23,727
-5,298
| -18% | -$333K |
|
80
Jabil
JBL
$33B
| $1.34M | 0.14% |
+50,950
| New | +$1.44M |
|
81
Graphic Packaging
GPK
$3.17B
| $1.33M | 0.14% |
+86,186
| New | +$1.3M |
|
|
EFII
82
DELISTED
Electronics for Imaging
EFII
| $1.32M | 0.14% |
+44,881
| New | +$1.5M |
|
|
K
83
DELISTED
Kellanova
K
| $1.32M | 0.14% |
+20,661
| New | +$1.24M |
|
|
ESL
84
DELISTED
Esterline Technologies
ESL
| $1.32M | 0.13% |
+17,633
| New | +$1.45M |
|
|
CIR
85
DELISTED
CIRCOR International, Inc
CIR
| $1.31M | 0.13% |
+26,908
| New | +$1.31M |
|
86
Element Solutions
ESI
$8.95B
| $1.31M | 0.13% |
+131,814
| New | +$1.37M |
|
87
Papa John's
PZZA
$984M
| $1.3M | 0.13% |
+23,250
| New | +$1.45M |
|
88
Ionis Pharmaceuticals
IONS
$8.6B
| $1.28M | 0.13% |
25,526
-25,431
| -50% | -$1.39M |
|
89
Ecovyst
ECVT
$1.32B
| $1.26M | 0.13% |
+76,827
| New | +$1.26M |
|
90
KLA
KLAC
$239B
| $1.26M | 0.13% |
+120,000
| New | +$1.27M |
|
91
Pegasystems
PEGA
$5.02B
| $1.25M | 0.13% |
+52,804
| New | +$1.42M |
|
|
MULE
92
DELISTED
MuleSoft, Inc.
MULE
| $1.24M | 0.13% |
+53,447
| New | +$1.21M |
|
93
Check Point Software Technologies
CHKP
$13B
| $1.24M | 0.13% |
+11,950
| New | +$1.3M |
|
|
AZPN
94
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $1.23M | 0.13% |
+18,607
| New | +$1.23M |
|
95
Molson Coors Class B
TAP
$7.79B
| $1.23M | 0.13% |
+15,000
| New | +$1.21M |
|
96
Kornit Digital
KRNT
$705M
| $1.21M | 0.12% |
+75,122
| New | +$1.18M |
|
97
British American Tobacco
BTI
$131B
| $1.21M | 0.12% |
+18,000
| New | +$1.17M |
|
98
KBR
KBR
$4.64B
| $1.15M | 0.12% |
+57,958
| New | +$1.1M |
|
|
STML
99
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.13M | 0.12% |
72,608
-11,602
| -14% | -$155K |
|
|
MSCC
100
DELISTED
Microsemi Corp
MSCC
| $1.12M | 0.11% |
21,600
-47,343
| -69% | -$2.49M |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q4 2017 Portfolio in Review
As of Q4 2017, Crestline Management held 234 positions worth $976M, up 36% from $719M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Crestline Management deployed $279M of net new capital in Q4 2017, opening 114 new positions and adding to 26 existing holdings. Its largest new stake was Denali Therapeutics: 20,574,298 shares worth $322M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 5.7% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Juno Therapeutics, Inc., an estimated $85.7M trimmed.
- Crestline Management's largest Q4 2017 buy was Denali Therapeutics: 20,574,298 shares worth $322M.
- Crestline Management added most to Ameriprise Financial in Q4 2017, an estimated $7.55M increase.
- Crestline Management's biggest Q4 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $85.7M.
- Crestline Management fully exited FNB Corp in Q4 2017, selling an estimated $8.22M.
- Crestline Management's ten largest holdings make up 76% of its $976M portfolio in Q4 2017.
- Crestline Management opened 114 new positions and closed 77 in Q4 2017.
- Crestline Management's portfolio value rose 36% quarter-over-quarter to $976M.
Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.